Quality of life in purely ocular myasthenia in Japan

Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC neurology 2014-07, Vol.14 (1), p.142-142, Article 142
Hauptverfasser:	Suzuki, Shigeaki, Murai, Hiroyuki, Imai, Tomihiro, Nagane, Yuriko, Masuda, Masayuki, Tsuda, Emiko, Konno, Shingo, Oji, Satoru, Nakane, Shunya, Motomura, Masakatsu, Suzuki, Norihiro, Utsugisawa, Kimiaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Anti-Inflammatory Agents - therapeutic use Care and treatment Cholinesterase Inhibitors - therapeutic use Complications and side effects Cross-Sectional Studies Diagnosis Drug therapy Ethics Female Health aspects Hospitals Humans Japan Male Medical research Medicine, Experimental Middle Aged Multivariate analysis Myasthenia gravis Myasthenia Gravis - complications Myasthenia Gravis - drug therapy Neurology Patients Prednisolone - therapeutic use Quality of Life Risk factors Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!